Mirriad shares crash 78% as cash crisis puts survival in doubt
Shares in Mirriad Advertising PLC (AIM:MIRI, OTCQX:MMDDF) plummeted 78% on Thursday after the company warned it may soon run out of money and could enter administration within days unless fresh funding is secured. The AIM-quoted virtual product placement specialist revealed that talks over a potential takeover had collapsed at the end of April, leaving the board scrambling for alternatives to keep the business afloat.
Seeing Machines posts rebound in automotive volumes as industry stabilises
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF), the driver monitoring technology group, reported an encouraging pick-up in production volumes for the third quarter of its financial year, following a broader slowdown across the automotive sector. The AIM-listed company, which supplies driver monitoring systems (DMS) to global carmakers, produced over 358,000 units in the three months to the end of March 2025, a 34% increase on the previous quarter.
Electric Guitar shares resume trading on AIM as company reboots with new board and cash shell strategy
Electric Guitar PLC (AIM:ELEG) is back on the market. The company's shares will resume trading on AIM Tuesday morning following a major board shake-up and the completion of a fundraising round that sets it up as a so-called “cash shell” - a listed vehicle with no active business but a mandate to acquire one.
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
Deposed AIM royalty ASOS enjoys a rare week in the sun
Once royalty of the AIM market, with a valuation that once put it on the cusp of the FTSE 100, ASOS PLC's (LSE:ASC)fall from grace has been rapid—and well documented. Earlier this week, its shares were languishing at levels last seen 17 years ago.
Jersey Oil and Gas investors to watch keenly as UK Govt's fiscal consultations proceed
Details will need to be fleshed out, but the UK government has heard the concerns of the North Sea industry, that's what Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) boss Andrew Benitz told investors as Westminster began a round of fiscal consultations. AIM-quoted Jersey and partner Dana Petroleum are poised to develop the Buchan project, which promises additional domestic gas supplies, though the project timeline is in the air amidst uncertainties over the tax regime for the North Sea.
KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said that its secured lenders have increased project financing facilities to $240 million, from $190 million.
Polarean Imaging inks partnership with US outpatient medical imaging firm
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) is teaming up with SimonMed Imaging, one of America's largest outpatient medical imaging providers. It will see the AIM-quoted firm's Xenon MRI platform delivered across the SimonMed network – starting with a site in Scottsdale, Arizona, later this year.
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?
AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Deltex Medical shares plunge 50% on proposed AIM cancellation and CEO resignation
Shares in Deltex Medical Group plc (AIM:DEMG) (AIM: DEMG) fell 50% following the announcement of a proposed delisting from AIM and leadership changes. The company attributed its decision to delist to the high costs of maintaining its AIM listing, estimated at £200,000 annually, representing 10% of its unaudited 2024 revenues of £2.1 million.
Orosur Mining Inc Announces Exercise of Warrants
Orosur Mining Inc Exercise of Warrants, Issue of Shares and Total Voting Rights LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM/TSXV:OMI), a minerals explorer and developer with projects in Colombia, Argentina and Nigeria, advises that, following an exercise of 179,856 warrants at an exercise price of US$0.0494 (approximately 3.984p) each, the Company will, issue 179,856 new common shares of no par value each ("Common Shares") for a total consideration of US$8,885. Application will be made for the 179,856 Common Shares, which rank pari passu with the existing Common Shares in issue, to be admitted to trading on AIM ("Admission").
Eden Research's regulatory wins keep coming at breakneck pace
Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't happen in a bubble. Rather, it's merely the latest in a long line of regulatory wins secured by the company in a couple of short years.
